|
1
|
Follézou JY and Bizon M: Cancer
chemotherapy induces a transient increase of serum-iron level.
Neoplasma. 33:225–231. 1986.PubMed/NCBI
|
|
2
|
Mashiko S, Nagaoka I, Kitajima M, et al:
Evaluation of serum iron levels during FOLFOX4 and FOLFIRI
therapies. Exp Ther Med. 1:507–511. 2010.PubMed/NCBI
|
|
3
|
Watanabe T, Itabashi M, Shimada Y, et al:
Japanese Society for Cancer of the Colon and Rectum (JSCCR)
guidelines 2010 for the treatment of colorectal cancer. Int J Clin
Oncol. 17:1–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weitz J, Koch M, Debus J, et al:
Colorectal cancer. Lancet. 365:153–165. 2005. View Article : Google Scholar
|
|
5
|
Proctor MJ, Talwar D, Balmar SM, et al:
The relationship between the presence and site of cancer, an
inflammation-based prognostic score and biochemical parameters.
Initial results of the Glasgow Inflammation Outcome Study. Br J
Cancer. 103:870–876. 2010. View Article : Google Scholar
|
|
6
|
McMillan DC: An inflammation-based
prognostic score and its role in the nutrition-based management of
patients with cancer. Proc Nutr Soc. 67:257–262. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McMillan DC: Systemic inflammation,
nutritional status and survival in patients with cancer. Curr Opin
Clin Nutr Metab Care. 12:223–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roxburgh CS and McMillan DC: Role of
systemic inflammatory response in predicting survival in patients
with primary operable cancer. Future Oncol. 6:149–163. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Balkwill F and Mantovani A: Inflammation
and cancer: back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mantovani A, Romero P, Palucka AK and
Marincola FM: Tumour immunity: effector response to tumour and role
of the microenvironment. Lancet. 371:771–783. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McDonald B, Spicer J, Giannais B, et al:
Systemic inflammation increases cancer cell adhesion to hepatic
sinusoids by neutrophil mediated mechanisms. Int J Cancer.
125:1298–1305. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Colotta F, Allavena P, Sica A, et al:
Cancer-related inflammation, the seventh hallmark of cancer: links
to genetic instability. Carcinogenesis. 30:1073–1081. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marsik C, Kazemi-Shirazi L, Schickbauer T,
et al: C-reactive protein and all-cause mortality in a large
hospital-based cohort. Clin Chem. 54:343–349. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goldwasser P and Feldman J: Association of
serum albumin and mortality risk. J Clin Epidemiol. 50:693–703.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deans C and Wigmore SJ: Systemic
inflammation, cachexia and prognosis in patients with cancer. Curr
Opin Clin Nutr Metab Care. 8:265–269. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsushima H, Ito N, Tamura S, et al:
Circulating transforming growth factor beta 1 as a predictor of
liver metastasis after resection in colorectal cancer. Clin Cancer
Res. 7:1258–1262. 2001.PubMed/NCBI
|
|
18
|
Toiyama Y, Fujikawa H, Kawamura M, et al:
Evaluation of CXCL10 as a novel serum marker for predicting liver
metastasis and prognosis in colorectal cancer. Int J Oncol.
40:560–566. 2012.PubMed/NCBI
|
|
19
|
Sharma R, Zucknick M, London R, et al:
Systemic inflammatory response predicts prognosis in patients with
advanced-stage colorectal cancer. Clin Colorectal Cancer.
7:331–337. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ponka P: Cellular iron metabolism. Kidney
Int Suppl. 69:S2–S11. 1999. View Article : Google Scholar
|
|
21
|
Aisen P, Enns C and Wessling-Resnick M:
Chemistry and biology of eukaryotic iron metabolism. Int J Biochem
Cell Biol. 33:940–959. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Papanikolaou G and Pantopoulos K: Iron
metabolism and toxicity. Toxicol Appl Pharmacol. 202:199–211. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Knutson M and Wessling-Resnick M: Iron
metabolism in the reticuloendothelial system. Crit Rev Biochem Mol
Biol. 38:61–88. 2003. View Article : Google Scholar
|
|
24
|
Krause A, Neitz S, Magert HJ, et al:
LEAP-1, a novel highly disulfide-bonded human peptide, exhibits
antimicrobial activity. FEBS Lett. 480:147–150. 2000.PubMed/NCBI
|
|
25
|
Park CH, Valore EV, Waring AJ, et al:
Hepcidin, a urinary antimicrobial peptide synthesized in the liver.
J Biol Chem. 276:7806–7810. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kemna EH, Tjalsma H, Willems HL and
Swinkels DW: Hepcidin: from discovery to differential diagnosis.
Haematologica. 93:90–97. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pigeon C, Ilyin G, Courselaud B, et al: A
new mouse liver-specific gene, encoding a protein homologous to
human antimicrobial peptide hepcidin, is overexpressed during iron
overload. J Biol Chem. 276:7811–7819. 2001. View Article : Google Scholar
|
|
28
|
Nicolas G, Bennoun M, Devaux I, et al:
Lack of hepcidin gene expression and severe tissue iron overload in
upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad
Sci USA. 98:8780–8785. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nemeth E, Tuttle MS, Powelson J, et al:
Hepcidin regulates cellular iron efflux by binding to ferroportin
and inducing its internalization. Science. 306:2090–2093. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nicolas G, Chauvet C, Viatte L, et al: The
gene encoding the iron regulatory peptide hepcidin is regulated by
anemia, hypoxia, and inflammation. J Clin Invest. 110:1037–1044.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nemeth E, Valore EV, Territo M, et al:
Hepcidin, a putative mediator of anemia of inflammation, is a type
II acute-phase protein. Blood. 101:2461–2463. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nemeth E, Rivera S, Gabayan V, et al: IL-6
mediates hypoferremia of inflammation by inducing the synthesis of
the iron regulatory hormone hepcidin. J Clin Invest. 113:1271–1276.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pietrangelo A, Dierssen U, Valli L, et al:
STAT3 is required for IL-6-gp130-dependent activation of hepcidin
in vivo. Gastroenterology. 132:294–300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vokurka M, Krijt J, Sulc K and Necas E:
Hepcidin mRNA levels in mouse liver respond to inhibition of
erythropoiesis. Physiol Res. 55:667–674. 2006.PubMed/NCBI
|
